Pharmaceutical Network November 4th. After the acquisition of Meridodon health consumer goods on October 1, Germany's Bayer Group，Bayer Group yesterday (November 3) confirmed to the "Daily Economic News" reporter，The company has completed the acquisition of all shares of Dianhong Pharmaceutical Group Company。

 

Company representation，This acquisition has strengthened the development of health stake online sports bettingconsumer stake betting appgoods business，It helps Bayer Medical Care to enter the leading position in the field of non -prescription drugs (OTC) in critical growth countries。

 

The reporter learned，With the completion of the acquisition of Merhadon health consumer goods business and the local Dianhong Pharmaceutical Industry，It will further establish the position of Bayer's position in the non -prescription drug business & mdash; & mdash; already ranked second in the field of non -prescription drugs。

 

The purchase price is 3.6 billion yuan

 

February this year，The company announced the acquisition of Dianhong Pharmaceuticals of Dianhong Pharmaceuticals of local private enterprises。Data display，Mainly producing non -prescription drugs (OTC) and traditional Chinese herbal products for treating various gynecological diseases。Bayer paid the acquisition price of 3.6 billion yuan (about 460 million euros)。

 

& ldquo; The acquisition further proves that our determination to enrich our life science product portfolio through global strategic mergers & rdquo;，Bayer Management Board Chairman Malgin? Dix said in a statement，& ldquo; The acquisition of the acquisition of Merck health consumer goods business we recently completed，Promote us to become the leading multinational enterprise in the field of non -prescription drugs in China。& rdquo;

 

China ONA Pharmaceutical stake betting appAssociation My stake betting appRanking Display，Dianhong Pharmaceutical is one of the top ten companies in OTC。Its main products include & ldquo; Kang Wang posted a lotion & rdquo;、& ldquo; King Pi Kang & rdquo; et al.。Except for business in China，Dianhong Pharmaceutical's products are still in Nigeria、Vietnam、Sales of countries such as Myanmar and Cambodia。

 

The reporter learned，Bayer's acquisition of the equity of Dianhong Pharmaceutical is the second time the company's large -scale acquisition of Chinese pharmaceutical companies，The business previously acquired is also in the field of non -prescription medicine。

 

2006，Bye ear spending 1.072 billion yuan to acquire three major non -prescription drug brands of Dongsheng Technology Qidong Gaigi Pharmaceutical Co., Ltd. & mdash; & ldquo;、& ldquo; Xiaobai & rdquo; syrup and & ldquo; Xinli & rdquo; cough syrup，Become the top 10 OTC companies in China。

 

Pioneering non -prescription business

 

In recent years，Non -prescription business has always been the focus of Bayer's development。In 2004, I spent 24 billion yuan to accept Roche's non -prescription business，After the acquisition is successful，Bayer from a company that is not rich in OTC products，Yuejin becomes the third company in the field of non -prescription business field。

 

In May this year，The company also announced stake sports betting appa high price of $ 14.2 billion stake sports betting appin Merck health stake online sports bettingconsumer goods business，It mainly includes treating colds、Allergy、rhinitis and flu、Dermatology products and gastrointestinal products，The transaction was completed on October 1, 2014。

 

& ldquo; We still continue to strengthen life science business，I acquired Merck's health stake online sports bettingconsumer goods business，This transaction has been completed in October。& rdquo; Dixe once said，Acquisition Merck enables Bayer Medical Care to ranks second in the world in the field of non -prescription medicine。

 

Bayer's third quarter financial report display，Company sales increased 5.6%，reached 10.187 billion euros，Among them, medical care and crop science have maintained a strong growth trend。

 

& ldquo; This has something to do with Bayer's strategy，Bayer is now gradually focusing on life science business，I hope to become a life science company in the future。& rdquo; A person in the pharmaceutical industry told reporters，& ldquo; The acquisition is the fastest way。& rdquo;